<DOC>
	<DOCNO>NCT00101972</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , RAV12 , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . PURPOSE : This phase I trial study side effect best dose RAV12 treat patient metastatic recurrent adenocarcinoma .</brief_summary>
	<brief_title>RAV12 Treating Patients With Metastatic Recurrent Adenocarcinoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose RAV12 patient metastatic recurrent adenocarcinoma . - Determine toxicity profile drug patient . - Determine pharmacokinetics immunogenicity drug patient . - Determine , preliminarily , antitumor activity drug patient . OUTLINE : This open-label , dose-escalation study . Patients receive RAV12 IV 2 hour 2-3 time per week week 1-4 ( course 1 ) . Patients evaluated response day 43 . Patients achieve partial complete response may eligible receive additional course RAV12 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos RAV12 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Up 15 additional patient treat MTD 1 patient group ( e.g. , colorectal , pancreatic , gastroesophageal , adenocarcinoma ) . After completion study treatment , patient follow within 4 week every 6-12 month thereafter . PROJECTED ACCRUAL : A total 75 patient accrue study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma Metastatic recurrent disease Not curable standard therapy Must fail least 1 , 3 , prior therapy metastatic recurrent disease Patients colorectal breast adenocarcinoma must fail least 2 prior therapy Must least stable disease 3 month last treatment prior recent disease progression Meets 1 follow criterion : At least 1 measurable site disease ≥ 2 cm radiography Evaluable disease could reliably consistently follow , deem principal investigator RAAG12 expression confirmed* immunohistochemistry NOTE : *Not require patient colon , pancreatic , gastric adenocarcinoma No evidence residual recurrent CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Not specify Menopausal status Not specify Performance status ECOG 01 Life expectancy More 3 month Hematopoietic Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL ( transfusion allow ) Absolute neutrophil count ≥ 1,500/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN γglutamyl transferase ≤ 2.5 time ULN Adequate hepatic function sufficient undergo study therapy Renal Creatinine &lt; 1.5 mg/dL Adequate renal function sufficient undergo study therapy Cardiovascular No New York Heart Association class III IV heart disease No thrombosis within past 3 month , include follow : Deep vein thrombosis Myocardial infarction Stroke Adequate cardiac function sufficient undergo study therapy Pulmonary No pulmonary embolism within past 3 month No significant pulmonary compromise , particularly dependence supplemental oxygen asneeded continuous basis Adequate pulmonary function sufficient undergo study therapy Immunologic No active viral , bacterial systemic fungal infection require parenteral therapy within past 4 week No history chronic recurrent infection require continual antiviral , antifungal , antibacterial agent No know hypersensitivity murine recombinant protein , polysorbate 80 , excipient contain study drug Other Amylase lipase normal No primary malignancy within past 3 year except follow : Treated nonmelanoma skin cancer Carcinoma situ cervix biopsy Squamous intraepithelial lesion cervix PAP smear Localized prostate cancer ( Gleason score &lt; 6 ) Resected melanoma situ No serious medical condition would preclude study participation No dementia alter mental status would preclude give informed consent Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy At least 3 halflives since prior monoclonal antibody therapy No concurrent vaccination No concurrent prophylactic hematologic growth factor Chemotherapy At least 4 week since prior chemotherapy Endocrine therapy No concurrent steroid except follow : Inhaled , ophthalmic , nasal steroid Stable dose oral prednisone ( equivalent ) ≤ 10 mg/day Radiotherapy At least 4 week since prior radiotherapy Surgery More 4 week since prior major surgery Other More 4 week since prior investigational agent Prior oral antiviral , antifungal , antibacterial therapy allow provided therapy complete within past week No concurrent antineoplastic therapy No concurrent immunosuppressive medication No concurrent investigational agent No concurrent vitamins except approve medical monitor Concurrent daily multivitamin allow Concurrent bisphosphonates allow provided patient stable dose ≥ 1 month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>adenocarcinoma bladder</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma extrahepatic bile duct</keyword>
	<keyword>adenocarcinoma gallbladder</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma squamous metaplasia gallbladder</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>endometrial adenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>salivary gland adenocarcinoma</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>vaginal adenocarcinoma</keyword>
	<keyword>vaginal clear cell adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage IVA vaginal cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage IVB vaginal cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>recurrent vaginal cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>